BACKGROUND: Whether people living with HIV who have not received antiretroviral therapy (ART) and have high CD4 cell counts have higher mortality than the general population is unknown. We aimed to examine this by analysis of pooled data from industrialised countries. METHODS: We merged data on demographics, CD4 cell counts, viral-load measurements, hepatitis C co-infection status, smoking status, date of death, and whether death was AIDS-related or not from 23 European and North American cohorts. We calculated standardised mortality ratios (SMRs) standardised by age, sex, and year, stratifying by risk group. Data were included for patients aged 20-59 years who had at least one CD4 count greater than 350 cells per microL while ART naive. All pre-ART CD4 counts greater than 350 cells per microL from January, 1990, to December, 2004, were included. We investigated mortality for four risk groups--men who have sex with men, heterosexual people, injecting drug users, and those at other or unknown risk. The association between CD4 cell count and death rate was investigated by use of Poisson regression methods. FINDINGS: Data were analysed for 40,830 patients contributing 80,682 person-years of follow-up. Of 419 deaths, 401 were used in the SMR analysis: 100 men who have sex with men (SMR 1.30, 95% CI 1.06-1.58); 68 heterosexual people (2.94, 2.28-3.73); 203 injecting drug users (9.37, 8.13-10.75); and 30 in the other or unknown risk category (4.57, 3.09-6.53). Compared with CD4 counts of 350-499 cells per microL, death rate was lower in patients with counts of 500-699 cells per microL (adjusted rate ratio 0.77, 95% CI 0.61-0.95) and counts of 700 cells per microL (0.66, 0.52-0.85). INTERPRETATION: In HIV-infected ART-naive patients with high CD4 cell counts, death rates were raised compared with the general population. In men who have sex with men this was modest, suggesting that a substantial proportion of the increased risk in other groups is due to confounding by other factors. Even though the increased risk is small, new studies of potential benefits of ART in this group are merited. FUNDING: European Commission, FP6. European AIDS Treatment Network (NEAT). Project number LSHP-CT-2006-037570. Copyright 2010 Elsevier Ltd. All rights reserved.
BACKGROUND: Whether people living with HIV who have not received antiretroviral therapy (ART) and have high CD4 cell counts have higher mortality than the general population is unknown. We aimed to examine this by analysis of pooled data from industrialised countries. METHODS: We merged data on demographics, CD4 cell counts, viral-load measurements, hepatitis C co-infection status, smoking status, date of death, and whether death was AIDS-related or not from 23 European and North American cohorts. We calculated standardised mortality ratios (SMRs) standardised by age, sex, and year, stratifying by risk group. Data were included for patients aged 20-59 years who had at least one CD4 count greater than 350 cells per microL while ART naive. All pre-ARTCD4 counts greater than 350 cells per microL from January, 1990, to December, 2004, were included. We investigated mortality for four risk groups--men who have sex with men, heterosexual people, injecting drug users, and those at other or unknown risk. The association between CD4 cell count and death rate was investigated by use of Poisson regression methods. FINDINGS: Data were analysed for 40,830 patients contributing 80,682 person-years of follow-up. Of 419 deaths, 401 were used in the SMR analysis: 100 men who have sex with men (SMR 1.30, 95% CI 1.06-1.58); 68 heterosexual people (2.94, 2.28-3.73); 203 injecting drug users (9.37, 8.13-10.75); and 30 in the other or unknown risk category (4.57, 3.09-6.53). Compared with CD4 counts of 350-499 cells per microL, death rate was lower in patients with counts of 500-699 cells per microL (adjusted rate ratio 0.77, 95% CI 0.61-0.95) and counts of 700 cells per microL (0.66, 0.52-0.85). INTERPRETATION: In HIV-infected ART-naivepatients with high CD4 cell counts, death rates were raised compared with the general population. In men who have sex with men this was modest, suggesting that a substantial proportion of the increased risk in other groups is due to confounding by other factors. Even though the increased risk is small, new studies of potential benefits of ART in this group are merited. FUNDING: European Commission, FP6. European AIDS Treatment Network (NEAT). Project number LSHP-CT-2006-037570. Copyright 2010 Elsevier Ltd. All rights reserved.
Authors: Caroline A Sabin; Achim Schwenk; Margaret A Johnson; Brian Gazzard; Martin Fisher; John Walsh; Chloe Orkin; Teresa Hill; Richard Gilson; Kholoud Porter; Philippa Easterbrook; Valerie Delpech; Loveleen Bansi; Clifford Leen; Mark Gompels; Jane Anderson; Andrew N Phillips Journal: AIDS Date: 2010-03-13 Impact factor: 4.177
Authors: Ard van Sighem; Sven Danner; Azra C Ghani; Luuk Gras; Roy M Anderson; Frank de Wolf Journal: J Acquir Immune Defic Syndr Date: 2005-10-01 Impact factor: 3.731
Authors: Rainer Weber; Caroline A Sabin; Nina Friis-Møller; Peter Reiss; Wafaa M El-Sadr; Ole Kirk; Francois Dabis; Matthew G Law; Christian Pradier; Stephane De Wit; Börje Akerlund; Gonzalo Calvo; Antonella d'Arminio Monforte; Martin Rickenbach; Bruno Ledergerber; Andrew N Phillips; Jens D Lundgren Journal: Arch Intern Med Date: 2006 Aug 14-28
Authors: Scott M Hammer; Joseph J Eron; Peter Reiss; Robert T Schooley; Melanie A Thompson; Sharon Walmsley; Pedro Cahn; Margaret A Fischl; Jose M Gatell; Martin S Hirsch; Donna M Jacobsen; Julio S G Montaner; Douglas D Richman; Patrick G Yeni; Paul A Volberding Journal: JAMA Date: 2008-08-06 Impact factor: 56.272
Authors: Fiona C Lampe; Colette J Smith; Sara Madge; Sabine Kinloch-de Loes; Mervyn Tyrer; Caroline A Sabin; Clinton Chaloner; Mike Youle; Margaret A Johnson; Andrew N Phillips Journal: Arch Intern Med Date: 2007-04-09
Authors: Andrew N Phillips; Brian Gazzard; Richard Gilson; Philippa Easterbrook; Margaret Johnson; John Walsh; Clifford Leen; Martin Fisher; Chloe Orkin; Jane Anderson; Deenan Pillay; Valerie Delpech; Caroline Sabin; Achim Schwenk; David Dunn; Mark Gompels; Teresa Hill; Kholoud Porter; Abdel Babiker Journal: AIDS Date: 2007-08-20 Impact factor: 4.177
Authors: Timothy J Wilkin; Christina M Lalama; John McKinnon; Rajesh T Gandhi; Nina Lin; Alan Landay; Heather Ribaudo; Lawrence Fox; Judith S Currier; John W Mellors; Roy Gulick; Allan R Tenorio Journal: J Infect Dis Date: 2012-06-27 Impact factor: 5.226
Authors: Stephen T Wright; Andrew Carr; Ian Woolley; Michelle Giles; Jennifer Hoy; David A Cooper; Matthew G Law Journal: J Acquir Immune Defic Syndr Date: 2011-09-01 Impact factor: 3.731
Authors: Margaret T May; Robert S Hogg; Amy C Justice; Bryan E Shepherd; Dominique Costagliola; Bruno Ledergerber; Rodolphe Thiébaut; M John Gill; Ole Kirk; Ard van Sighem; Michael S Saag; Gemma Navarro; Paz Sobrino-Vegas; Fiona Lampe; Suzanne Ingle; Jodie L Guest; Heidi M Crane; Antonella D'Arminio Monforte; Jörg J Vehreschild; Jonathan A C Sterne Journal: Int J Epidemiol Date: 2012-11-12 Impact factor: 7.196
Authors: Constanza Lucero; Berta Torres; Agathe León; Marta Calvo; Lorna Leal; Iñaki Pérez; Montserrat Plana; Mireia Arnedo; Josep Mallolas; Josep M Gatell; Felipe García Journal: AIDS Res Hum Retroviruses Date: 2013-04-18 Impact factor: 2.205
Authors: Alan R Lifson; Elizabeth M Krantz; Lynn E Eberly; Matthew J Dolan; Vincent C Marconi; Amy C Weintrob; Nancy F Crum-Cianflone; Anuradha Ganesan; Patricia L Grambsch; Brian K Agan Journal: AIDS Res Ther Date: 2011-01-18 Impact factor: 2.250
Authors: Enwu Liu; Keming Rou; Jennifer M McGoogan; Lin Pang; Xiaobin Cao; Changhe Wang; Wei Luo; Sheena G Sullivan; Julio S G Montaner; Marc Bulterys; Roger Detels; Zunyou Wu Journal: J Infect Dis Date: 2013-04-16 Impact factor: 5.226